Results: Science Environmental Protection Co., Ltd. Beat Earnings Expectations And Analysts Now Have New Forecasts
It's been a pretty great week for Science Environmental Protection Co., Ltd. (SHSE:688480) shareholders, with its shares surging 10% to CN¥34.00 in the week since its latest annual results. It l
Science Environmental Protection Co., Ltd.'s (SHSE:688480) Stock Has Seen Strong Momentum: Does That Call For Deeper Study Of Its Financial Prospects?
Most readers would already be aware that Science Environmental Protection's (SHSE:688480) stock increased significantly by 15% over the past week. Given that stock prices are usually aligned with a
Dongwu Securities released a research report on April 23 stating that it gave Syns (688480.SH) a buy rating. The main reasons for the rating include: 1) the comprehensive solution business increased in 2023, and the net operating cash flow increased by 15
Dongwu Securities released a research report on April 23 stating that it gave Syns (688480.SH) a buy rating. The main reasons for the rating include: 1) the comprehensive solution business increased in 2023, and the net operating cash flow increased by 156%; 2) Zijin cooperation continued to deepen, and overseas revenue grew rapidly. (Mainichi Keizai Shimbun)
Guohai Securities released a research report on April 23 stating that it gave Syns (688480.SH) a buying rating. The main reasons for the rating include: 1) comprehensive solutions, significant increase in overseas revenue, and stable profitability; 2) pro
Guohai Securities released a research report on April 23 stating that it gave Syns (688480.SH) a buying rating. The main reasons for the rating include: 1) comprehensive solutions, significant increase in overseas revenue, and stable profitability; 2) profit quality is good, but contract debt has declined, so we need to pay attention to the progress of obtaining solution orders. (Mainichi Keizai Shimbun)
Sainz (688480): Strong increase in performance and continued deepening cooperation with Zijin
The incident described that 2023A achieved revenue of 808 million yuan, a year-on-year increase of 47.47%; net profit to mother of 90 million yuan, an increase of 36.39% over the previous year; net profit after deducting non-attributable net profit of 75 million yuan, an increase of 35.02 million yuan over the previous year
Sainz (688480): Overseas business breaks through in 2023, investment income contributes to growth in 2024Q1
Event: On April 21, 2024, Sainz released the 2023 Annual Report and 2024 Quarterly Report: Achieved operating income of 808 million yuan (yoy +47.47%) and net profit of 903 to mother in 2023
Express News | Sainz: Net profit increased 492.69% year-on-year in the first quarter
Synes (688480.SH) reported 2023 annual results, net profit of 90,3279 million yuan, a year-on-year increase of 36.39%
Syns (688480.SH) released its 2023 annual report. The company achieved operating income of 8.0 during the reporting period...
Sainz (688480): Zijin Pharmaceutical's net profit increased in 24Q1
There was a high increase in new orders in 2023, benefiting from the 2024Q1 net profit increase of Zijin Pharmaceutical's merger and acquisition, and the company achieved revenue of 808 million yuan in 2023, +47.47% over the same period last year, and a net profit of 90.33 million yuan.
Science Environmental Protection Co., Ltd.'s (SHSE:688480) P/E Is Still On The Mark Following 25% Share Price Bounce
Those holding Science Environmental Protection Co., Ltd. (SHSE:688480) shares would be relieved that the share price has rebounded 25% in the last thirty days, but it needs to keep going to repair the
Sainz (688480) 2023 Earnings Report Review: Performance Exceeds Forecast and the Brand Effect Helps Rapid Development
Incident: On February 23, 2024, the company released its 2023 performance report. The company achieved operating income of 808 million yuan, an increase of 47.39%; net profit to mother was 93 million yuan, an increase of 40.79%.
Sainz (688480): Acquired the remaining 61% of Zijin Pharmaceutical's shares to achieve technology, channel, and business collaboration with copper extractants as the core
Investment highlights: On January 13, 2024, Sainz issued an announcement on the acquisition of participating subsidiaries and related transactions. It plans to use its own capital of 183 million yuan to acquire the participating subsidiary Fujian Zijin Mineral Processing Pharmaceutical Co., Ltd. (hereinafter referred to as
Syns (688480.SH) performance report: 2023 net profit of 93.244 million yuan, a year-on-year increase of 40.79%
GLONGHUI, Feb. 23 | SAINCE (688480.SH) announced the 2023 Annual Results Report. During the reporting period, the company achieved operating income of 807.926 million yuan, a year-on-year increase of 47.39%; achieved net profit attributable to owners of the parent company of 93.244 million yuan, an increase of 40.79% year on year; realized net profit attributable to owners of the parent company after deducting non-recurring profit and loss of 75.970 million yuan, an increase of 36.27% year on year.
Sainz (688480): Net profit returned to mother in '23 exceeded the performance forecast limit
The company's earnings report's net profit in 23 was +41% year-on-year, exceeding the upper limit of the performance forecast. The company issued the 2023 performance report: it is expected to achieve operating income of 808 million yuan in 2023 (the performance forecast range is 7.5-8.5 million yuan
Sainz (688480): Optimistic about the growth and profitability of the copper extractant business
Copper extractants have good growth and profitability. A successful merger and acquisition of Zijin Pharmaceutical will significantly increase the company's profits. On January 30, the company's 2nd Extraordinary General Meeting of Shareholders in '24 voted to acquire 61% of Fujian Zijin Mineral Processing Pharmaceutical Co., Ltd.
Returns On Capital At Science Environmental Protection (SHSE:688480) Have Stalled
To find a multi-bagger stock, what are the underlying trends we should look for in a business? In a perfect world, we'd like to see a company investing more capital into its business and ideally the
Sainz (688480.SH): Sales of Zijin Pharmaceuticals are less affected by seasonal fluctuations
GLONGHUI, January 17 | When receiving research from institutional investors, Sains (688480.SH) recently said that sales of Zijin Pharmaceuticals are less affected by seasonal fluctuations. They mainly sell products in batches. There are phased sales, and revenue fluctuations are mainly delivery issues. If some customers increase production capacity and the amount required for initial production is high, it will lead to higher sales. The increase in sales in the fourth quarter of 2023 is mainly due to the large number of orders placed during the current period due to the fact that some major customers have reached the replenishment cycle.
Syns (688480.SH): Zijin Pharmaceutical currently accounts for less than 30% of domestic sales, and the market is mainly overseas
Gelonghui, January 17, 丨 While receiving research from institutional investors, Ge Longhui (688480.SH) recently said that Zijin Pharmaceutical currently accounts for less than 30% of domestic sales, and the market is mainly overseas. At present, the domestic market is relatively saturated, and overseas markets can increase their own market share by competing with BASF and others through product cost advantages and service advantages. Zijin Pharmaceuticals accounts for a relatively low sales volume in the Chilean market, mainly in the Democratic Republic of the Congo (DRC), and accounts for about 1/2 of Zijin Pharmaceuticals' current revenue.
Sainz (688480): Proposed acquisition of Zijin Pharmaceutical to enhance the copper extractant layout
Incident: Sainz plans to acquire 61% of Zijin Pharmaceutical's shares and strengthen the distribution of mineral processing agents and copper extractants. On January 13, Sainz announced that it plans to use its own capital of 183 million yuan to acquire the participating subsidiary Fujian Zijin Mineral Processing Pharmaceutical Co., Ltd. 6
Syns (688480.SH) plans to acquire 61% of Zijin Pharmaceutical's shares to hold all of its shares
Syns (688480.SH) announced that the company plans to use its own capital of 183 million yuan to acquire participating shareholders...
No Data